IART · XBRL financial data

Integra Lifesciences Holdings financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (IART's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	397*	369	418	381	443*	383	416	402	435*	392	419	411
Cost of goods and services sold	171*	162	192	181	194*	188	206	195	214*	175	199	201
Selling, general and administrative	163*	166	195	177	179*	181	180	169	169*	178	172	165
Operating income (loss)	36*	4	(3)	(8)	36*	(15)	(513)	12	23*	11	19	19
Interest income	5*	5	5	5	5*	4	5	5	4*	4	4	5
Interest expense	14*	14	19	19	19*	19	21	23	24*	22	23	23
Other income (expense)	2*	(1)	1	2	1*	(0)	(2)	(1)	1*	4	4	15
Income tax expense (benefit)	9*	(2)	(3)	(10)	3*	(5)	(47)	(1)	6*	2	0	1
Net income (loss)	20*	(3)	(12)	(11)	19*	(25)	(484)	(5)	(2)*	(5)	4	15
Earnings per share, basic USD per share	0.25*	(0.04)	(0.16)	(0.14)	0.25*	(0.33)	(6.31)	(0.07)	(0.02)*	(0.06)	0.06	0.19
Earnings per share, diluted USD per share	0.25*	(0.04)	(0.16)	(0.14)	0.25*	(0.33)	(6.31)	(0.07)	(0.02)*	(0.06)	0.06	0.19
Weighted average shares, basic millions of shares	78*	78	77	76	76*	76	77	77	77*	77	77	77
Weighted average shares, diluted millions of shares	78*	78	77	76	76*	76	77	77	77*	77	78	79

Fiscal quarters (IART's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	276	592	215	215	246	239	218	232	235	237	214	252
Short-term investments	33	71	82	62	27	34	36	36	29	29	60	60
Accounts receivable	259	241	271	248	272	252	285	262	279	264	267	249
Inventory	390	403	422	437	429	445	465	489	493	495	492	464
Total current assets	1,058	1,416	1,112	1,100	1,082	1,107	1,143	1,144	1,160	1,172	1,191	1,190
Property and equipment, net	340	345	374	391	406	423	435	437	444	447	446	441
Right-of-use asset	156	152	147	146	144	138	137	138	141	137	137	136
Goodwill	1,055	1,040	1,105	1,117	1,097	1,105	616	615	615	613	611	608
Total assets	3,782	4,078	4,074	4,066	4,037	4,053	3,668	3,646	3,602	3,578	3,563	3,508
Accrued liabilities	101	112	102	132	122	137	131	133	130	133	108	102
Total current liabilities	307	302	328	913	922	918	930	364	456	347	331	329
Lease liability, non-current	167	170	170	168	167	161	159	161	163	160	163	161
Total liabilities	2,194	2,480	2,540	2,544	2,492	2,529	2,629	2,609	2,559	2,535	2,520	2,441
Retained earnings	947	944	931	920	940	915	431	425	423	419	423	438
Total stockholders' equity	1,588	1,598	1,534	1,522	1,545	1,524	1,039	1,038	1,043	1,042	1,043	1,067
Total liabilities and equity	3,782	4,078	4,074	4,066	4,037	4,053	3,668	3,646	3,602	3,578	3,563	3,508
Common shares outstanding (cover page) millions of shares	78	79	78	77	77	78	78	78	78	78	78	78

Fiscal quarters (IART's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	20*	(3)	(12)	(11)	19*	(25)	(484)	(5)	(2)*	(5)	4	15
Stock-based compensation	6*	6	7*	4*	7*	2	5*	6*	6*	5	6*	3*
Net cash from operating activities	59*	16	40*	22*	51*	(11)	9*	41*	12*	10	23*	96*
Purchases of property and equipment	25*	15	30*	30*	30*	29	20*	15*	17*	15	12*	10*
Net cash from investing activities	(57)*	(54)	(322)*	(10)*	(4)*	(36)	(22)*	(16)*	(35)*	(15)	(43)*	(10)*
Share repurchases	0*	0	50*	0*	2*	—	—	0*	0*	—	—	0*
Net cash from financing activities	(7)*	359	(94)*	(20)*	(7)*	35	(21)*	(10)*	24*	8	(1)*	(46)*
Net change in cash	3*	316	(377)*	(0)*	31*	(7)	(21)*	14*	3*	2	(22)*	38*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Integra Lifesciences Holdings	252	411	96*	77.8M	—	Q3 FY26 10-QSep 30, 2026
Establishment Labs Holdings	71	68	(17)*	29.8M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
NovoCure	97	193	23	116.9M	—	Q3 FY26 10-QSep 30, 2026
Biolife Solutions	24	not reported	6.3*	48.9M	—	Q2 FY26 10-QJun 30, 2026
SI-BONE	35	56	5.9*	45.1M	—	Q3 FY26 10-QSep 30, 2026
Embecta	215	272	42*	56.7M	—	Q3 FY26 10-QJun 30, 2026
Mimedx Group	121	62	3.9*	145.9M	—	Q3 FY26 10-QSep 30, 2026
CONMED	48	336	49*	29.8M	—	Q3 FY26 10-QSep 30, 2026
Alphatec Holdings	80	221	19*	155.1M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.